Topical Azithromycin and Clarithromycin Inhibit Acute and Chronic Skin Inflammation in Sensitized Mice, with Apparent Selectivity for Th2-Mediated Processes in Delayed-Type Hypersensitivity
- 462 Downloads
Macrolide antibiotics inhibit the secretion of Th1 cytokines while their effects on the release of Th2 cytokines are variable. We investigated molecular and cellular markers of Th1- and Th2-mediated inflammatory mechanisms and the anti-inflammatory activity of azithromycin and clarithromycin in phorbol 12-myristate 13-acetate (PMA) and oxazolone (OXA)-induced skin inflammation. Dexamethasone (50 μg/ear), azithromycin, and clarithromycin (500 μg/ear) reduced TNF-α and interleukin (IL)-1β concentration in ear tissue by inhibiting inflammatory cell accumulation in PMA-induced inflammation. In OXA-induced early delayed-type hypersensitivity (DTH), the macrolides (2 mg/ear) and dexamethasone (25 μg/ear) reduced ear tissue inflammatory cell infiltration and secretion of IL-4 while clarithromycin also decreased IFN-γ concentration. Macrolides showed better activity when administered after the challenge. In OXA-induced chronic DTH, azithromycin (1 mg/ear) reduced the number of ear tissue mast cells and decreased the concentration of IL-4 in ear tissue and of immunoglobulin (Ig)E in serum. Clarithromycin (1 mg/ear) reduced serum IgE concentration, possibly by a mechanism independent of IL-4, while both macrolides attenuated mast cell degranulation. In conclusion, azithromycin and clarithromycin attenuate pro-inflammatory cytokine production and leukocyte infiltration during innate immune reactions, while selectively affecting Th2 rather than Th1 immunity in DTH reactions.
KEY WORDSmacrolide anti-inflammatory activity oxazolone PMA skin inflammation Th2 cytokines
This work was supported by GlaxoSmithKline Research Centre Zagreb Ltd. The authors wish to thank I. Glojnari, Ph.D. for team leading, and Ms. S. Skender and I. ubela and Mr. H. Poduška for their excellent technical assistance.
- 6.Wildfeuer, A., H. Laufen, D. Muller-Wening, and O. Haferkamp. 1989. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Drug Research/Arzneimittelforschung 39: 755–758.Google Scholar
- 8.Čuli, O., V. Erakovi, I. Cepelak, K. Bariši, K. Brajša, Ž. Ferenči, R. Galovi, I. Glojnari, Z. Manojlovi, V. Muni, R. Novak-Mirceti, V. Paviči-Beljak, M. Sui, M. Veljača, T. Žani-Grubiši, and M.J. Parnham. 2002. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. European Journal of Pharmacology 450: 277–289.CrossRefGoogle Scholar
- 15.Pinto, L.A., C. Camozzato, M. Avozani, D. Cantarelli Machado, M.H. Jones, R. Tetelbom Stein, and P.M. Condessa Pitrez. 2004. Effect of Clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease. Revista do Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo 59: 99–103.Google Scholar
- 18.Tkalčevi, V.I., B. Bošnjak, B. Hrvači, M. Bosnar, N. Marjanovi, Ž. Ferenči, K. Šitum, O. Čuli, M.J. Parnham, and V. Erakovi. 2006. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. European Journal of Pharmacology 539: 131–138.CrossRefGoogle Scholar
- 19.Tkalčevi, V.I., B. Bošnjak, I. Pašali, B. Hrvači, K. Šitum, M.D. Kramari, I. Glojnari, and V.E. Haber. 2008. The anti-inflammatory activity of clarithromycin inhibits TNFα production and prolongs survival following lipopolysaccharide administration in mice. International Journal of Antimicrobial Agents 32: 195–196.CrossRefGoogle Scholar
- 24.Napoletano, M., E. Moriggi, A. Mereu, F. Ornaghi, G. Morazzoni, R. Longoni, C. Riva, L. Pacchetti, and F. Pellacini. 2004. Macrolide compounds endowed with anti-inflammatory activity. PCT/EP2003/012071. International publication number WO 2004/013153 A2.Google Scholar
- 26.Young, J.M., and L.M. De Young. 1989. Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents. In Pharmacological methods in the control of inflammation, 1st ed, ed. J.Y. Chang and A.J. Lewis, 215–231. New York: Alan R. Liss, Inc.Google Scholar
- 27.Takeshita, K., I. Yamagishi, M. Harada, S. Otumo, T. Nakagawa, and Y. Mizushima. 1989. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs under Experimental and Clinical Research 15: 527–533.PubMedGoogle Scholar
- 28.Bosnar, M., B. Bošnjak, S. Čuži, B. Hrvači, N. Marjanovi, I. Glojnari, O. Čuli, M.J. Parnham, and V.E. Haber. 2009. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1β. Journal of Pharmacology and Experimental Therapeutics 331: 104–113.PubMedCrossRefGoogle Scholar
- 30.Zunic, M., G.M. Bahr, G.C. Mudde, J.G. Meingassner, and C. Lam. 1998. MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammation. The Journal of Investigative Dermatology 111: 77–82.PubMedCrossRefGoogle Scholar
- 31.Elder, D., R. Elenitsas, C. Jaworsky, and B. Johnson Jr. (eds.). 1997. Lever's histopathology of the skin, 8th ed. Philadelphia: Lippincott–Raven Publishers.Google Scholar